#1 Clinical Trials Search in Europe

Study on the Effects of Alpha-1 Antitrypsin and Prednisolone in Patients with Severe Alcohol-Related Hepatitis

2 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a treatment for Alcohol-Associated Hepatitis, a liver condition caused by excessive alcohol consumption. The study will use a medication called Alpha-1 Antitrypsin, which is a protein that helps reduce inflammation in the body. The treatment involves administering this protein through an intravenous infusion, which means it is given directly into the bloodstream through a vein.

The purpose of the study is to evaluate how effective Alpha-1 Antitrypsin is in reducing inflammation in patients with severe forms of this liver condition. Participants in the study will receive the treatment once a week for four weeks. Some participants will receive a placebo instead of the active treatment. The study will monitor the effects of the treatment over a period of time to see if it helps improve the condition of the liver and overall health of the participants.

Throughout the study, participants will have regular check-ups to assess their health and any changes in their condition. The study aims to gather information on the safety and effectiveness of Alpha-1 Antitrypsin as a potential treatment for Alcohol-Associated Hepatitis. This research could provide valuable insights into new ways to manage and treat this liver disease.

1 joining the study

Upon joining the study, the patient will be informed about the procedures and will provide written consent to participate.

The patient must meet specific criteria, such as being 18 years or older, having severe alcohol-associated hepatitis, and not being in intensive care.

2 baseline visit

The baseline visit occurs on Day 1. During this visit, initial assessments are conducted, including blood tests to measure certain markers in the blood.

The patient will begin receiving the standard treatment for their condition.

3 medication administration

The patient will receive an intravenous infusion of human alpha1-proteinase inhibitor at a dose of 120 mg per kilogram of body weight once a week for four weeks.

This medication is administered in addition to the standard treatment.

4 follow-up visits

Follow-up visits are scheduled to monitor the patient’s response to the treatment. The first follow-up visit is on Day 8, where blood tests will be repeated.

Additional follow-up visits occur on Day 29 and continue until the end of the study period, which is approximately 90 days from the start.

5 end of study visit

The final visit occurs around Day 90. During this visit, the patient’s overall health and response to the treatment are evaluated.

The study aims to assess the effect of the treatment on inflammation and other health markers.

Who Can Join the Study?

  • Must be a male or female who is at least 18 years old.
  • Must have severe Alcohol-Associated Hepatitis (AAH), which is a liver condition caused by drinking too much alcohol. This is determined by a specific score called Maddrey’s discriminant function score, which should be 32 or higher.
  • Must not have ACLF (Acute-on-Chronic Liver Failure) or only have ACLF Grade 1 at the time of screening.
  • Must have consumed an average of more than 80 grams of alcohol per day for men, or more than 60 grams per day for women, over the past 3 months. This is based on what the patient reports.
  • Must understand and agree to follow the study procedures and provide written consent by signing a form.
  • Must be an outpatient or a hospitalized patient who is not in the Intensive Care Unit (ICU) at the time of screening.
  • For women who can have children, they must have a negative urine pregnancy test, not be breastfeeding, and agree to use highly effective birth control methods during the study. This can include not having sex, having a partner who had a vasectomy, or using approved birth control methods like condoms with spermicide, an intrauterine device, or prescription hormonal contraceptives.
  • For men who are sexually active with women who can have children, they must agree to use a condom with spermicide and another approved birth control method from the time they start the study treatment and for at least 90 days after the last dose. They must also not donate sperm during this time.
  • Must be able to speak and read German well enough to fully understand everything that is said and written in the study.

Who Cannot Join the Study?

  • Patients who are pregnant or breastfeeding cannot participate.
  • Individuals with a history of severe allergic reactions to the study medication are excluded.
  • Patients with other serious health conditions that might interfere with the study are not eligible.
  • People who are currently participating in another clinical trial are not allowed to join.
  • Individuals with a history of drug or alcohol abuse that could affect the study results are excluded.
  • Patients who have received certain medications that might interfere with the study treatment are not eligible.
  • Anyone who cannot comply with the study procedures or follow-up visits is excluded.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Medizinische Universitaet Innsbruck Innsbruck Austria

Other Sites

No sites found in this category

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Austria Austria
Recruiting
03.02.2025

Trial locations

Investigated drugs:

Alpha-1 Antitrypsin (A1AT) is a protein that helps protect the lungs and liver from damage. In this clinical trial, it is being used to see if it can reduce inflammation in patients with severe alcohol-associated hepatitis. The medication is given through an intravenous infusion, which means it is delivered directly into the bloodstream. The goal is to see if this treatment can help improve the condition of patients by reducing the harmful effects of inflammation on the liver.

Investigated diseases:

Alcohol-Associated Hepatitis – This disease is a liver condition caused by excessive alcohol consumption, leading to inflammation of the liver. It often occurs after years of heavy drinking, but can also develop after a short period of excessive alcohol intake. The inflammation can cause symptoms such as jaundice, abdominal pain, and nausea. As the condition progresses, it may lead to liver scarring and impaired liver function. The severity of symptoms can vary, with some individuals experiencing mild discomfort while others may have severe liver damage. The progression of the disease depends on continued alcohol use and the body’s response to liver inflammation.

Trial ID:
2024-515794-99-00
Protocol code:
EARTH
NCT ID:
NCT06582329
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of N-acetylcysteine and prednisolone combination versus extended prednisolone treatment in patients with severe alcoholic hepatitis

    Recruiting

    3 1 1
    Investigated drugs:
    France

  • Study on the Effectiveness of N-Acetylcysteine and Methylprednisolone for Patients with Severe Acute Alcoholic Hepatitis

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Spain